Advertisement
Advertise here Publish your press releases here Sponsor BioPortfolio
Follow us on Twitter Sign up for daily news and research emails Contributors wanted

Latest "irbesartan amlodipine irbesartan Hypertension" News Stories

04:59 EDT 25th July 2014 | BioPortfolio

Here are the most relevant search results for "irbesartan amlodipine irbesartan Hypertension" found in our extensive news archives from over 250 global news sources.

More Information about irbesartan amlodipine irbesartan Hypertension on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about irbesartan amlodipine irbesartan Hypertension for you to read. Along with our medical data and news we also list irbesartan amlodipine irbesartan Hypertension Clinical Trials, which are updated daily. BioPortfolio also has a large database of irbesartan amlodipine irbesartan Hypertension Companies for you to search.

Showing "irbesartan amlodipine irbesartan Hypertension" News Articles 1–25 of 1,100+

Extremely Relevant

Human medicines European public assessment report (EPAR): Irbesartan Zentiva (previously Irbesartan Winthrop), irbesartan, Revision: 14, Authorised

Human medicines European public assessment report (EPAR): Irbesartan Hydrochlorothiazide Zentiva (previously Irbesartan Hydrochlorothiazide Winthrop), irbesartan / hydrochlorothiazide, Revision: 18, Authorised

Human medicines European public assessment report (EPAR): Irbesartan Teva, irbesartan, Revision: 4, Authorised

Human medicines European public assessment report (EPAR): Irbesartan Teva, irbesartan, Revision: 5, Authorised

Human medicines European public assessment report (EPAR): Irbesartan/Hydrochlorothiazide Teva, irbesartan / hydrochlorothiazide, Revision: 6, Authorised

Huahai Pharmaceutical Gets U.S. FDA Nod For Irbesartan Tablets

Huahai Pharmaceutical said it has won U.S. FDA approval for its generic irbesartan (Avapro) hydrochlorothiazide tablets under an Abbreviated New Drug Application to sell the products in the U.S. market.

Human medicines European public assessment report (EPAR): Sabervel, irbesartan, Revision: 1, Authorised

Human medicines European public assessment report (EPAR): Karvea, irbesartan, Revision: 30, Authorised

Human medicines European public assessment report (EPAR): Aprovel, irbesartan, Revision: 31, Authorised

Human medicines European public assessment report (EPAR): CoAprovel, irbesartan / hydrochlorothiazide, Revision: 29, Authorised

Human medicines European public assessment report (EPAR): Karvezide, irbesartan / hydrochlorothiazide, Revision: 30, Authorised

Relevant

Efficacy of olmesartan/amlodipine combination therapy in reducing ambulatory blood pressure in moderate-to-severe hypertensive patients not controlled by amlodipine alone

FDA accepts Symplmed's Prestalia NDA for hypertension treatment

Symplmed announced today that the U.S. Food and Drug Administration has accepted for review its New Drug Application (NDA) for investigational drug Prestalia, the first single-pill, fixed-dose combination (FDC) of perindopril arginine and amlodipine...

Dr Reddy’s launches generic amlodipine/atorvastatin

Indian generics giant Dr Reddy’s announced on 27 March 2014 the launch of its generic amlodipine/atorvastatin tablets in the US.

Zacras® Combination Tablets LD and Zacras® Combination Tablets HD, Fixed-Dose Combination of Azilsartan and Amlodipine, and Azilva® Tablets 10mg, Treatment for Hypertension, are Now Available in Japan

News Release

Takeda's NDA of hypertension drug Zacras approved in Japan

The Japanese Ministry of Health, Labour and Welfare has approved Takeda Pharmaceutical's new drug application (NDA) of Zacras tablets, a fixed-dose combination (FDC) of azilsartan (generic name) and amlodipine besylate hydrochloride (generic name, am…

Novartis Japan Files Application For Orally Disintegrating Exforge

Novartis filed an application in Japan for the approval of an orally disintegrating version of its ARB and calcium channel blocker combination Exforge (valsartan/amlodipine) for the treatment of hypertension.

Udenafil vs Amlodipine in Secondary Raynaud's Phenomenon

Is udenafil or amlodipine more effective in the treatment of secondary Raynaud's phenomenon? Rheumatology

Hypertension: Treatment-resistant hypertension—a risk factor for ESRD

Failure to achieve blood pressure control in patients with hypertension despite the use of three or more antihypertensive drugs is becoming more frequent. Although treatment-resistant hypertension has been associated with an increased risk of cardiov...

Hypertension - Pipeline Review, H1 2014

Recently added to the BioPortfolio report store, Hypertension - Pipeline Review, H1 2014 is a new report from Global Markets Direct published on 2014-02-27. This 238-page report is available in PDF from $2000. Hypertension - Pipeline Review, H1 2014 Summary Global Markets Direct’s, ‘Hypertension - Pipeline Review, H1 2014’, provides an overview of the Hypertension’s therapeutic pipeline....

Which New Hypertension Guidelines Are the Best?

Three separate hypertension guidelines were released last year. Speakers at HYPERTENSION 2014 were tasked with convincing the audience which set of recommendations is the best. Heartwire

Hypertension going untreated in US Hispanic community

There is a significant deficit in recognition and control of hypertension in the Hispanic population of the United States, according to a new study published in American Journal of Hypertension (AJH).

Resistant Hypertension or Noncompliance? A Push for Answers

Hypertension doctors gathering here are turning with renewed attention to the questions: how many patients truly have "resistant" hypertension, and what's the best way to get blood pressure down? Heartwire

The pathophysiology of hypertension in patients with obesity

Obesity and hypertension are associated with high morbidity and mortality. In this Review, DeMarco and colleagues describe the pathophysiological mechanisms that can lead to obesity-related hypertension and discuss potential therapies that might be u...

FDA Accepts New Drug Application for Symplmed’s Prestalia® for the Treatment of Hypertension

- First fixed-dose combination of ACE inhibitor, perindopril arginine, and calcium channel blocker, amlodipine besylate, to be reviewed in the U.S. - - Symplmed to Streamline Prescription Delivery Process through Proprietary DyrctAxess™ - Symplmed announced today that the U.S. Food and Drug Administration (FDA) has accepted for review...


Search BioPortfolio:
Advertisement

News Quicklinks

Advertisement